Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001178913-25-002111
Filing Date
2025-06-05
Accepted
2025-06-05 16:05:29
Documents
18
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A zk2533282.htm   iXBRL DEF 14A 904012
6 GRAPHIC image0.jpg GRAPHIC 7645
7 GRAPHIC image1.jpg GRAPHIC 102876
8 GRAPHIC image00002.jpg GRAPHIC 2315
  Complete submission text file 0001178913-25-002111.txt   2088771

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE entx-20241231.xsd EX-101.SCH 6178
3 XBRL DEFINITION FILE entx-20241231_def.xml EX-101.DEF 5506
4 XBRL LABEL FILE entx-20241231_lab.xml EX-101.LAB 15327
5 XBRL PRESENTATION FILE entx-20241231_pre.xml EX-101.PRE 5545
20 EXTRACTED XBRL INSTANCE DOCUMENT zk2533282_htm.xml XML 244936
Mailing Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002
Business Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002 972-2-532-7151
Entera Bio Ltd. (Filer) CIK: 0001638097 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38556 | Film No.: 251027092
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)